Traws Pharma, Inc.
TRAW
$1.86
$0.2012.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.79% | -1.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.79% | -1.75% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 1.79% | -1.75% | |||
| SG&A Expenses | -20.77% | -0.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.39% | -37.93% | |||
| Operating Income | 1.42% | 38.17% | |||
| Income Before Tax | 171.82% | -253.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 171.82% | -253.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 171.82% | -253.06% | |||
| EBIT | 1.42% | 38.17% | |||
| EBITDA | 1.40% | 38.18% | |||
| EPS Basic | -91.86% | 401.84% | |||
| Normalized Basic EPS | 131.75% | -10.24% | |||
| EPS Diluted | -92.14% | 401.84% | |||
| Normalized Diluted EPS | 130.65% | -10.24% | |||
| Average Basic Shares Outstanding | 126.21% | 220.27% | |||
| Average Diluted Shares Outstanding | 134.30% | 220.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||